YOLFTbeta
Viking Therapeutics Inc

Viking Therapeutics Inc

VKTX · NASDAQ · Healthcare / Biotechnology

29.22USD+1.64 (+5.95%)

Price History

Full chart

Market Stats

Previous Close27.58
Open27.44
Day Range26.69 – 29.96
52-Week Range25.77 – 43.15
Volume8.84M
Market Cap4.43B
P/E (TTM)0.00
Forward P/E0.00
EPS-4.67
Dividend Yield0.00%
Beta0.68
50-Day Avg33.89
200-Day Avg33.31

About

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Brian Lian Ph.D.
  • Employees65
  • Headquarters9920 Pacific Heights Boulevard, San Diego, CA, United States, 92121, USA
  • Websitehttps://www.vikingtherapeutics.com

Leadership

  • Dr. Brian Lian Ph.D.President, CEO & Director · b. 1966
  • Mr. Gregory S. Zante CPAChief Financial Officer · b. 1971
  • Mr. Michael MorneauVice President of Finance & Administration · b. 1965
  • Ms. Katherine MercierVice President of Quality & Compliance
  • Mr. Kenneth J. Herman M.B.A.Senior Vice President of Commercial, Marketing & Sales
  • Dr. Geoffrey E. Barker Ph.D.Chief Development Officer
  • Mr. Neil Aubuchon B.A., M.B.A.Chief Commercial Officer · b. 1970
  • Dr. Nils U. Olsson Ph.D.Senior Vice President of Technical Operations
  • Dr. Hubert C. Chen M.D., M.P.H.Chief Medical Officer · b. 1969

Financials

Income Statement

Currency: USD2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue--00000010.73K10.70K0000
Growth (%)----------0.28%-100.00%---
Cost of Revenue--00000260.00K277.00K296.00K291.00K292.00K346.00K431.00K
Gross Profit--00000-260.00K10.73K-296.00K-291.00K-292.00K-346.00K-431.00K
Gross Margin--------100.00%-2766.10%----
Operating Expense--23.47M12.00M13.85M19.07M26.16M32.43M42.67M55.39M70.06M100.53M150.57M392.91M
Operating Income-438.56-101.08K-23.47M-12.00M-13.85M-19.07M-26.16M-32.69M-42.66M-55.68M-70.36M-100.83M-150.92M-393.34M
Operating Margin---------397558.48%-520343.89%----
EBITDA-109.64K-121.70K-21.26M-21.36M1.15M442.88K4.66M-25.37M3.77M-54.68M-68.52M-100.83M-109.52M-359.15M
EBITDA Margin--------35117.93%-510942.90%----
Net Income-444.11-146.25K-21.88M-23.40M-14.73M-20.58M-22.06M-25.78M-39.49M-54.99M-68.87M-85.89M-109.96M-359.64M
Net Income Margin---------368045.85%-513877.21%----
R&D275.4811.61K22.22M6.97M9.00M13.74M19.04M23.56M31.93M44.98M54.23M63.81M101.64M344.95M
R&D as % of Total Revenue--------297558.48%420343.89%----
Interest Expense-24.55K628.68K1.02M2.03M1.95M562.00K146.00K106.00K18.00K59.00K88.00K94.00K56.00K
Interest Expense % of Total Revenue--------987.79%168.21%----

Balance Sheet

Currency: USD2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets-180.39K3.04M15.44M14.54M22.12M302.31M284.26M256.50M210.66M168.53M368.49M908.32M715.73M
Total Liabilities105.42K431.00K25.17M6.71M6.49M8.66M4.56M7.14M12.16M8.78M23.21M20.07M28.04M76.67M
Total Equity-105.42K-250.60K-22.13M8.72M8.04M13.46M297.75M277.12M244.34M201.88M145.32M348.42M880.28M639.06M
Cash-179.62K755.86K768.55K3.08M8.99M24.78M8.38M29.12M26.37M36.63M55.52M26.68M165.81M
Total Debt42.75K278.75K1.57M2.15M3.27M3.45M-662.00K359.00K29.00K1.56M1.26M1.12M137.00K
Net Debt42.75K99.13K812.53K1.38M194.08K-5.54M-24.78M-7.71M-28.76M-26.34M-35.07M-54.26M-25.56M-165.67M

Cash Flow

Currency: USD2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-200-78.23K-1.59M-8.73M-11.07M-14.76M-18.75M-24.75M-21.78M-47.59M-48.40M-73.38M-87.79M-278.69M
Investing Cash Flow---13.47M-13.47M3.03M-1.73M-265.73M7.46M41.57M37.96M54.75M-179.09M-553.37M341.39M
Financing Cash Flow200257.85K2.17M22.21M10.35M22.40M300.27M887.00K950.00K6.88M4.16M271.38M612.46M76.44M
Capital Expenditure00000000000000
Free Cash Flow-200-78.23K-1.59M-8.73M-11.07M-14.76M-18.75M-24.75M-21.78M-47.59M-48.40M-73.38M-87.79M-278.69M
Dividends Paid---022.29K0--------
FCF to OCF100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%
Dividend Paid to FCF---0.00%-0.20%0.00%--------

Earnings

Report DateJun 11, 2015Aug 13, 2015Nov 5, 2015Mar 8, 2016May 10, 2016Aug 10, 2016Nov 10, 2016Mar 21, 2017May 10, 2017Aug 9, 2017Nov 8, 2017Mar 7, 2018May 9, 2018Aug 9, 2018Nov 7, 2018Mar 13, 2019May 2, 2019Aug 1, 2019Nov 5, 2019Feb 26, 2020Apr 30, 2020Jul 29, 2020Oct 28, 2020Feb 17, 2021Apr 28, 2021Jul 28, 2021Nov 3, 2021Feb 9, 2022Apr 27, 2022Jul 27, 2022Oct 26, 2022Feb 8, 2023Apr 26, 2023Jul 26, 2023Oct 25, 2023Feb 7, 2024Apr 24, 2024Jul 24, 2024Oct 23, 2024Feb 5, 2025Apr 23, 2025Jul 23, 2025Oct 22, 2025Feb 11, 2026Apr 29, 2026Jul 29, 2026Oct 28, 2026
EPS Estimate0.28-0.13-0.32-0.43-0.43-0.22-0.23-0.20-0.18-0.19-0.20-0.17-0.12-0.12-0.11-0.10-0.09-0.09-0.12-0.13-0.12-0.14-0.15-0.15-0.17-0.20-0.21-0.19-0.19-0.21-0.23-0.23-0.24-0.20-0.22-0.25-0.28-0.27-0.24-0.27-0.31-0.44-0.67-0.90-0.91-1.211.00
EPS Actual-1.40-1.07-0.53-0.56-0.40-0.22-0.20-0.18-0.23-0.21-0.22-0.14-0.08-0.13-0.11-0.07-0.07-0.11-0.08-0.10-0.13-0.13-0.13-0.15-0.19-0.20-0.17-0.16-0.21-0.23-0.21-0.26-0.25-0.19-0.23-0.25-0.26-0.20-0.22-0.32-0.41-0.58-0.81-1.38-1.37-1.10-
Surprise-600.00%-723.08%-65.63%-30.23%6.98%0.00%13.04%10.00%-27.78%-10.53%-10.00%17.65%33.33%-8.33%0.00%30.00%22.22%-22.22%33.33%23.08%-8.33%7.14%13.33%0.00%-11.76%0.00%19.05%15.79%-10.53%-9.52%8.70%-13.04%-4.17%5.00%-4.55%0.00%7.14%25.93%8.33%-18.52%-32.26%-31.82%-20.90%-53.33%-50.55%9.09%-
TimingAfter-hoursPre-marketPre-marketAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours

Key Statistics & Ratios

Market Cap4.43B
Enterprise Value4.36B
Trailing P/E0.00
Forward P/E0.00
PEG Ratio-0.03
Price / Sales0.00
Price / Book11.90
EPS-4.67
Book Value3.50
Revenue (TTM)0
Gross Profit (TTM)0
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-88.85%
Return on Assets-51.86%
Shares Outstanding124.51M
Shares Float113.73M
Beta0.68
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 19 analystsTarget 94.82
  • Strong Buy
    10
  • Buy
    7
  • Hold
    2

Ownership Breakdown

Institutions
61.16%
Insiders
2.86%
Retail / Other
35.98%

Top Institutional Holders

  • BlackRock Inc
    6.88M5.90%
  • FMR Inc
    6.02M5.16%
  • Vanguard Capital Management, LLC
    5.01M4.30%
  • Vanguard Portfolio Management, LLC
    4.46M3.83%
  • State Street Corp
    4.40M3.77%
  • Two Sigma Investments LLC
    3.94M3.38%
  • Morgan Stanley - Brokerage Accounts
    3.01M2.58%
  • Geode Capital Management, LLC
    2.08M1.78%
  • American Century Companies Inc
    1.82M1.56%
  • Ameriprise Financial Inc
    1.68M1.44%
  • D. E. Shaw & Co LP
    1.61M1.38%
  • UBS Group AG
    1.35M1.16%

Top Fund Holders

  • State Street® SPDR® S&P® Biotech ETF
    3.78M3.29%
  • Vanguard MStar Total Stk Mkt Idx Invest
    3.51M3.06%
  • Vanguard Small Cap Index
    2.54M2.21%
  • Vanguard MStar Small Cap Growth Indx Inv
    1.46M1.27%
  • American Century Heritage Inv
    1.33M1.16%
  • Jupiter Merian Glb Eq Abs Rt I USD Acc
    1.30M1.13%
  • Fidelity Advisor Growth Opps M
    1.06M0.93%
  • CT (Lux) American Smaller Com 9U USD
    957.61K0.83%